Payment overview · 2025
General Payments
$963.42
40 reported records · 16 companies
Healthcare provider profile · identity verified
Steven W, Graeca, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · DU BOIS, PA · NPI 1295765030
Verified facts
What the public records show
CMS Open Payments records show Steven W, Graeca, D.O. received $963.42 in general payments during 2025 across 40 reported records.
Astellas Pharma US Inc accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 745 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $313.92 | 32.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $118.31 | 12.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $114.66 | 11.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.05 | 8.9% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $55.75 | 5.8% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.86 | 4.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.79 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.88 | 3.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.29 | 3.1% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $25.77 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.76 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.24 | 2.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.21 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.67 | 1.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.08 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.18 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $684.49 | 37 |
| Education | $278.93 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $114.66 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $86.05 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.74 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $50.55 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $48.75 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.79 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 745 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 109 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 73 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
102 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
745 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1172 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 846 | 141 |
| Eliquis | Apixaban | 745 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 710 | 104 |
| Furosemide | Furosemide | 592 | 73 |
| Gabapentin | Gabapentin | 510 | 58 |
| Lisinopril | Lisinopril | 508 | 101 |
| Potassium Chloride | Potassium Chloride | 408 | 77 |
| Trazodone Hcl | Trazodone Hcl | 399 | 71 |
| Mirtazapine | Mirtazapine | 398 | 58 |
| Famotidine | Famotidine | 347 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 55 |
| Omeprazole | Omeprazole | 334 | 66 |
| Memantine Hcl | Memantine Hcl | 323 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 71 |
| Bumetanide | Bumetanide | 309 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 305 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 57 |
| Metformin Hcl | Metformin Hcl | 269 | 49 |
| Donepezil Hcl | Donepezil Hcl | 260 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 44 |
| Sertraline Hcl | Sertraline Hcl | 243 | 34 |
| Allopurinol | Allopurinol | 240 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 231 | 40 |
| Prednisone | Prednisone | 191 | 89 |
| Carvedilol | Carvedilol | 179 | 29 |
| Xarelto | Rivaroxaban | 178 | 15 |
| Simvastatin | Simvastatin | 177 | 30 |
| Cephalexin | Cephalexin | 174 | 93 |
| Levetiracetam | Levetiracetam | 167 | 20 |
| Jardiance | Empagliflozin | 166 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 164 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 161 | 17 |
| Losartan Potassium | Losartan Potassium | 159 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 22 |
| Montelukast Sodium | Montelukast Sodium | 141 | 24 |
| Warfarin Sodium | Warfarin Sodium | 141 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 30 |
| Entresto | Sacubitril/Valsartan | 129 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 21 |
| Farxiga | Dapagliflozin Propanediol | 109 | 15 |
| Lorazepam | Lorazepam | 105 | 43 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 103 | 16 |
| Myrbetriq | Mirabegron | 102 | 13 |
| Sucralfate | Sucralfate | 100 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 51 |
| Valsartan | Valsartan | 91 | 24 |
| Tramadol Hcl | Tramadol Hcl | 88 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 15 |
| Azithromycin | Azithromycin | 80 | 60 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 79 | 41 |
| Baclofen | Baclofen | 78 | suppressed |
| Lamotrigine | Lamotrigine | 78 | suppressed |
| Risperidone | Risperidone | 78 | 14 |
| Lactulose | Lactulose | 74 | suppressed |
| Rexulti | Brexpiprazole | 73 | suppressed |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Atenolol | Atenolol | 69 | suppressed |
| Dutasteride | Dutasteride | 69 | 16 |
| Finasteride | Finasteride | 67 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 66 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 66 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | suppressed |
| Nystatin | Nystatin | 63 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 27 |
| Ceftriaxone | Ceftriaxone Sodium | 56 | 34 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 16 |
| Rytary | Carbidopa/Levodopa | 49 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 42 |
| Torsemide | Torsemide | 48 | 14 |
| Humalog | Insulin Lispro | 46 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 46 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Metolazone | Metolazone | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 40 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 12 |
| Amoxicillin | Amoxicillin | 38 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Erythromycin | Erythromycin Base | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 36 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 31 |
| Fentanyl | Fentanyl | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 20 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 33 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | 25 |
| Insulin Lispro | Insulin Lispro | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 16 |
| Ozempic | Semaglutide | 30 | 13 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | 21 |
| Mupirocin | Mupirocin | 27 | 15 |
| Dilantin | Phenytoin Sodium Extended | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Fluconazole | Fluconazole | 24 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 23 | 19 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 23 | 13 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Procrit | Epoetin Alfa | 22 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 22 | 13 |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Colchicine | Colchicine | 21 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Mesalamine | Mesalamine | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Insulin Aspart | Insulin Aspart | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Pacerone | Amiodarone Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Ivermectin | Ivermectin | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 15 | 12 |
| Nyamyc | Nystatin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Ramipril | Ramipril | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propylthiouracil | Propylthiouracil | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $963.42 · 40 records | Astellas Pharma US Inc | AIRSUPRA, BREZTRI, CAMZYOS, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GLASSIA, JARDIANCE, NUPLAZID, PROLIA, PYRUKYND, REXULTI, SX-ONE MICROKNIFE, UBRELVY, VAXNEUVANCE, Veozah | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error